Definitions

from Wiktionary, Creative Commons Attribution/Share-Alike License.

  • noun A humanized monoclonal antibody under development for the treatment of certain cancers.

Etymologies

Sorry, no etymologies found.

Examples

  • Announced that the worldwide collaboration with Genentech, a wholly-owned member of the Roche Group, for the development of dacetuzumab will end in June 2010

    The Earth Times Online Newspaper

  • Fourth quarter 2009 expenses decreased compared to the fourth quarter of 2008 as a result of lower manufacturing costs for dacetuzumab and brentuximab vedotin, and decreased lintuzumab clinical trial costs.

    The Earth Times Online Newspaper

  • The increases in revenues were primarily driven by the earned portion of payments received under the company's dacetuzumab collaboration with Genentech.

    The Earth Times Online Newspaper

  • The increases in revenues were primarily driven by the earned portion of payments received under the company's dacetuzumab collaboration with Genentech.

    The Earth Times Online Newspaper

  • These revenues are generated from fees, milestones and reimbursements earned through the company's brentuximab vedotin, dacetuzumab and ADC collaborations.

    The Earth Times Online Newspaper

  • Announced that the worldwide collaboration with Genentech, a wholly-owned member of the Roche Group, for the development of dacetuzumab will end in June 2010

    The Earth Times Online Newspaper

  • In addition, Seattle Genetics has four other product candidates in ongoing clinical trials: lintuzumab (SGN-33), dacetuzumab (SGN-40), SGN-70 and SGN-75.

    The Earth Times Online Newspaper

  • In addition, Seattle Genetics has four other clinical-stage programs: lintuzumab (SGN-33), dacetuzumab (SGN-40), SGN-70 and SGN-75.

    Business Wire Travel News

  • Fourth quarter 2009 expenses decreased compared to the fourth quarter of 2008 as a result of lower manufacturing costs for dacetuzumab and brentuximab vedotin, and decreased lintuzumab clinical trial costs.

    The Earth Times Online Newspaper

  • Revenues are expected to include approximately $70 million related to the company's dacetuzumab collaboration that will end in June 2010, primarily related to cash amounts previously received.

    The Earth Times Online Newspaper

Comments

Log in or sign up to get involved in the conversation. It's quick and easy.